In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni raise $65M in new funding, enter strategic partnerships, secure patents, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Appointed LSI Alumni Trent Reutiman as its new CEO. As the company works towards regulatory approval of its ANA5 Advanced Neurovascular Access device, Reutiman will establish a new footprint for the company in the United States.
Announced the first close at €51M for its new Capricorn Healthtech Fund II to invest in innovative healthtech and medtech companies. The fund will target investment in 10-15 late-seed to Series B stage companies.
Appointed Greg Dachs as its Head of R&D to lead the next phase of development. With ample experience in scaling robotics, hardware, and technology, Dachs will play a critical role in advancing the company’s structural heart solutions.
Enrolled the first patient in the STRIDE clinical trial of its eShunt System for treating normal pressure hydrocephalus (NPH). This milestone brings CereVasc closer to validating its minimally invasive alternative to the standard of care, ventriculoperitoneal shunt surgery.
Raised $37M in a Series D funding round to expand the availability of GammaTile in the United States for patients with operable brain tumors. The funds will also support continued clinical evidence generation and commercial scaling efforts.
Formed a global strategic partnership with UpSurgeOn to deliver high-quality, simulation-based training solutions. The collaboration aims to enhance surgical training programs by incorporating UpSurgeOn’s portfolio into Inovus’ digital surgery platform.
Completed enrollment in its AVENTUS pivotal IDE trial for its Aventus Thrombectomy System, with 130 patients enrolled. The trial is a multicenter, prospective, single-arm trial to be conducted at 20+ clinical trial sites in the United States.
Secured a new patent in India for its Safety Sheath technology, adding to its U.S. patent issued in November 2023. As product development progresses through Phases 1 and 2, the company plans to submit for FDA approval later this year to advance its solution for preventing retained guidewires.
Published results from a landmark clinical study validating its patch-based polysomnography system. The study, one of the largest in sleep diagnostics, demonstrated the system’s accuracy and utility for home-based sleep monitoring.
Appointed LSI Alumni Paul LaViolette as CEO to lead the company’s strategic direction. With extensive experience scaling medtech companies and driving the adoption of innovative technologies, LaViolette will be a key part of the company’s next phase of growth.
Secured a new patent in China for its platform for real-time surgical leak detection, adding to its existing patents in the European Union, the United States, and Japan. This milestone strengthens Qaelon’s global intellectual property portfolio and bolsters its efforts to expand its reach.
Raised $28M to advance its microrobotic solutions for neurosurgery. The funds will support continued development, preparation for human trials in 2026, and the establishment of U.S. operations ahead of FDA approval and market entry.
Announced the initiation of the co-development of the SinaptiStim Precision Neuromodulation System, aimed at treating Alzheimer’s disease. The company remains on track to initiate pivotal clinical trials for the technology later this year.
Successfully finalized the first phase of pre-clinical testing of its TriClover technology. TriClover is a novel triple edge-to-edge transcatheter repair technology designed to provide a minimally invasive solution for treating tricuspid regurgitation.
Announced that the Royal Orthopaedic Hospital is leveraging its AI-powered platform to improve operating room efficiency and safety. The platform enhances workflow management and supports better decision-making during surgical procedures.
Welcomed Jason Helgerson, former New York Medicaid Director, and Dr. Alistair Erskine, Chief Digital Officer at Emory University, as Operating Partners. Their expertise will strengthen the firm’s focus on investments in healthtech innovation.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
